CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
EN
Home / Revolution Medicines, INC. (RVMD) / daraxonrasib
Forward catalyst · RVMD

daraxonrasib

Sponsor Revolution Medicines, INC. · listed as RVMD

READOUT Phase 3 Confidence: medium Source: clinicaltrials

daraxonrasib is a clinical-stage drug asset sponsored by Revolution Medicines, INC., listed as RVMD. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 1, 2027 (day precision, medium confidence), tied to trial NCT06881784. The asset is in Phase 3 and currently recruiting, studied in NSCLC (Non-small Cell Lung Cancer). It appears across 5 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2027-12-01
As disclosedDec 1, 2027
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06881784
PhasePHASE3
StatusRECRUITING
Lead sponsorRevolution Medicines, Inc.
Listed asRVMD
Condition(s)NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer; NSCLC; NSCLC (Non-small Cell Lung Carcinoma); NSCLC (Advanced Non-small Cell Lung Cancer)
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.

Get the full dataset — $499 →   More RVMD catalysts

Related catalysts and sponsor